Zbigniew M. Szczepiorkowski, MD, PhD
Title(s)
Professor of Pathology and Laboratory Medicine
Professor of Medicine
Department(s)
Pathology and Laboratory Medicine
Medicine
Education
1991 MD Medical Academy, Warsaw, Poland
1997 PhD Postgraduate Center of Medical Education, Warsaw, Poland
Programs
Immunology Program
Norris Cotton Cancer Center
Academic Analytics
View Profile
Contact Information
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon NH 03756
Office: Rubin 703
Phone: 603-650-7171
Fax: 603-650-4845
Email: ziggy@dartmouth.edu
Assistant: Paula Martell
Asst. Phone: 603-650-7114
Asst. Email: Paula.W.Martell@hitchcock.org
Professional Interests
Translational research leading to introduction of novel cellular therapies applied broadly across the field of medicine.
Evidence based approach to the use of therapeutic apheresis in clinical practice.
Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study. Antibody Titers in Transfusion Medicine: A Critical Reevaluation of Testing Accuracy, Reliability, and Clinical Use. Platelet components and bacterial contamination: hospital perspective 2022. Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study. Passive order auditing associated with reductions in red blood cell utilization: National blood shortage experience. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage. Obstetric and Newborn Weak D-Phenotype RBC Testing and Rh Immune Globulin Management Recommendations: Lessons From a Blinded Specimen-Testing Survey of 81 Transfusion Services. Wastewater-Based SARS-CoV-2 Surveillance in Northern New England. Standardization of cellular therapy terminology, coding and labeling: a review. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. |
|